1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Abnova Taiwan Corp.

Abnova Taiwan Corp.

TTWSE:4133
20.60
TWD
-0.30
(-1.44%)
0.74EPS
27.61P/E
1.24BMarket Cap
Abnova Taiwan Corp.
TWSE:4133
(Taiwan Stock Exchange)

Recent

price

20.60

P/E

ratio

27.61

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
7.65
7.61
7.47
7.46
7.05
7.38
7.48
7.85
7.04
6.84
7.54
7.46
6.8
6.31
5.87
5.8
5.7
Revenue per Share
2.4
1.93
1.28
1.17
1.06
0.73
0.91
0.97
0.76
0.05
0.6
0.47
1.24
0.72
1.02
-0.02
0.74
Basic EPS, GAAP
1.56
1.68
0.58
1.22
1.2
-1.55
-0.11
-0.34
0.08
1.01
1.61
1.52
2.08
0.78
0.71
-0.17
0.72
Free Cash Flow per Basic Share
1.44
1.92
1.92
1.15
1.05
0.97
0.66
0.39
0.8
0.6
0.1
0.6
0.46
0.8
0.72
0.9
- -
Dividend per Share
20.44
20.4
19.77
19.8
19.8
19.78
19.42
20.23
20.27
19.69
20
20.01
21.34
21.24
21.62
20.75
21.03
Book Value per Share
19.92
19.93
19.12
19.18
19.3
19.2
18.84
19.81
19.23
18.55
18.83
18.89
20.2
20.09
20.59
19.77
20.08
Tangible Book Value per Share
62
62
62
62
62
61
59
61
61
61
61
61
61
61
61
61
61
Basic Weighted Avg Shares
475
473
464
464
438
451
440
475
426
414
456
451
412
382
355
351
345
Sales/Revenue/Turnover
27.78
25.45
20.34
17.09
14.26
11.32
11.03
12.42
5.08
7.21
13.48
9.97
15.82
11.55
9.45
4.97
6.18
Operating Margin (%)
61
46
40
39
39
36
36
36
41
47
44
42
34
32
30
29
28
Depreciation Expense
149
120
79
73
66
45
54
59
46
3
37
28
75
44
62
-1
45
Net Income, GAAP
- -
7.31
18.74
17.63
15.19
19
6.12
19.08
- -
- -
25.53
21.84
21.18
9.97
15.82
- -
4.99
Effective Tax Rate (%)
31.37
25.36
17.09
15.72
14.98
9.95
12.17
12.41
10.83
0.79
8
6.28
18.18
11.43
17.34
-0.32
12.99
Profit Margin (%)
1,142
1,110
1,082
1,090
1,099
880
815
792
669
639
699
724
855
857
903
862
882
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
7
5
1
4
3
18
13
11
LT Debt
1,270
1,267
1,228
1,230
1,230
1,167
1,176
1,225
1,227
1,192
1,211
1,212
1,292
1,286
1,309
1,256
1,273
Total Equity
- -
8.78
6.1
5.29
4.29
3.41
3.85
3.94
- -
- -
3.51
2.78
4.02
3.27
2.2
- -
1.63
Return on Invested Capital (%)
- -
9.44
6.35
5.93
5.34
3.75
4.57
4.91
- -
- -
3.01
2.33
5.94
3.37
4.7
- -
3.56
Return on Capital (%)
12.02
9.45
6.35
5.93
5.34
3.75
4.57
4.91
3.76
0.27
3.04
2.34
5.98
3.39
4.75
-0.09
3.58
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
13
13
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
61
61
Market Capitalization
1,375
1,362
1,238

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
915
937
947
Cash, Cash Equivalents & STI
378
395
405
Accounts Receivable, Net
50
52
47
Inventories
469
470
478
Total Current Liabilities
54
66
65
Payables & Accruals
- -
- -
- -
ST Debt
5
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.79%
0.8%
-4.04%
Free Cash Flow
106.49%
-32.66%
-123.24%
Net Income, GAAP
97.31%
7.81%
-101.85%
Sales/Revenue/Turnover
-2.27%
-5.04%
-1.11%
Total Cash Common Dividend
48.91%
113.12%
25%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
85
92
90
88
355
2025
90
92
85
84
351
2026
88
88
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.44
0.3
0.05
0.22
1.02
2025
0.22
-0.6
0.19
0.17
-0.02
2026
0.28
0.1
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.72
2025
- -
- -
- -
- -
0.9
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Abnova (Taiwan) Corporation principally engages in the manufacturing and sales of antibodies and recombinant proteins. The company's core product portfolio includes monoclonal antibodies, polyclonal antibodies, protein fragments, full-length proteins, active proteins, antibody pairs, fluorescence in situ hybridization probes, and related assay kits. It provides specialized antibodies such as MaxPab, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. Abnova also offers integrated services encompassing gene synthesis, cytogenetics, peptide synthesis, protein expression, conjugation, antibody production, and assay development. Its products serve applications in medical testing reagents, agricultural testing, industrial purification, medical treatment, protein engineering, and research sectors. The company operates primarily in Taiwan, the Americas, and Europe, targeting academic institutions, research organizations, and pharmaceutical manufacturers. Founded in 2002 and headquartered in Taipei, Taiwan, Abnova has recently expanded into cell therapy markets with the launch of CellTX cell therapy reagents, reflecting a strategic diversification aligned with pharmaceutical industry evolution. The company reported solid earnings in recent quarters despite some year-to-year net income variation, underlining ongoing operational resilience. Abnova maintains a commitment to high-throughput, industrialized antibody production leveraging advanced IT management systems to optimize laboratory practices and production scalability. This comprehensive product and service suite positions Abnova as a significant player in biotechnology reagents and customized biological research tools in the health care sector.